Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. announced that CMND-100, its proprietary non-hallucinogenic drug candidate for Alcohol Use Disorder, met the primary safety and tolerability endpoint in its FDA-approved multinational Phase I/IIa clinical trial. The drug was well tolerated at escalating doses with no serious adverse events reported, supporting further clinic…